Jones Michael L 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Dec 7, 2020
Insider Transaction Report
Form 4
Jones Michael L
Exec. Director, Finance - PAO
Transactions
- Award
Emp. Stock Option (Right to Buy)
2020-12-03+5,000→ 5,000 totalExercise: $5.45From: 2020-12-03Exp: 2023-08-08→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.